ProfessionalsJack Sun

Jack Sun

Counsel

Counsel

Tel: +852-2846-0315
Fax: +852-3014-5819
jsun@paulweiss.com

email+852-2846-0315

Hong Kong

Suites 3601-06 & 3610, 36/F
Gloucester Tower, The Landmark
15 Queen’s Road, Central
Hong Kong
Fax: +852-3014-5819

+ vCard ADD TO CONTACTS

Practices
Corporate
Asia

Education

LL.B., Peking University Law School

Languages

Mandarin

Practices:
Corporate
Asia

Education

LL.B., Peking University Law School

Languages

Mandarin

A counsel in the Corporate Department, based in the firm’s Hong Kong office, Jack Sun focuses on China-related private equity investments, cross-border mergers and acquisitions and foreign direct investments.

He is fluent in English and Mandarin.

Related Resources

Silvercorp Metals Completes $150 Million Convertible Senior Notes Offering

Dec 02, 2024
Client News

Silvercorp Metals Completes $150 Million Convertible Senior Notes Offering

Paul, Weiss advised BMO Capital Markets Corp. as the representative for the initial purchasers in Silvercorp Metals Inc.’s private offering of $150 million aggregate principal amount of 4.75% convertible senior notes due 2029.

GSK Agrees to Acquire Autoimmune Disease Treatment From Chimagen Biosciences

Oct 29, 2024
Client News

GSK Agrees to Acquire Autoimmune Disease Treatment From Chimagen Biosciences

Paul, Weiss is advising UK-based GSK plc in its proposed acquisition of an investigational molecule used to treat autoimmune disease from Chimagen Biosciences, a China-based privately held biotechnology company.

DCP Capital Acquires Cargill’s Poultry Business in China

Jun 01, 2023
Client News

DCP Capital Acquires Cargill’s Poultry Business in China

Paul, Weiss is advising private equity firm DCP Capital in its acquisition of the China-based poultry business of Cargill, the world’s largest agribusiness company.

General Atlantic Invests in LePure Biotech

Jan 18, 2023
Client News

General Atlantic Invests in LePure Biotech

Paul, Weiss advised General Atlantic in its Series C investment in Shanghai LePure Biotech Co., Ltd. (LePure Biotech), a China-based single-use solutions provider for biopharmaceutical companies.

Considerations for Investors in Chinese VIE Structures

Oct 25, 2022
Publications

Considerations for Investors in Chinese VIE Structures

Recent regulatory developments in the U.S. and China, along with calls by investors for more transparency, have increased scrutiny on Chinese companies that are listed on U.S. stock exchanges using the “variable interest entities”…

KKR Invests in Ruichen Pet Hospital Group

Aug 24, 2022
Client News

KKR Invests in Ruichen Pet Hospital Group

Paul, Weiss advised KKR in its investment in Ruichen Pet Hospital Group Co., Ltd., a Chinese pet hospital chain.

Hans-Günther Herrmann and Jack Sun Co-Author Article on China’s FIE Reform, China Law & Practice

Oct 31, 2016
Publications

Hans-Günther Herrmann and Jack Sun Co-Author Article on China’s FIE Reform, China Law & Practice

Corporate counsel Hans-Günther Herrmann and associate Jack Sun co-authored an article in the November/December issue of China Law & Practice.

LOAD MORE SHOW LESS View More

Awards & Recognition

Judie Ng Shortell and Jack Sun Recognized by The Legal 500’s China Awards 2023

Dec 07, 2023
Awards

Judie Ng Shortell and Jack Sun Recognized by The Legal 500’s China Awards 2023

The Legal 500’s inaugural China Awards recognized corporate partner Judie Ng Shortell as “Lawyer of the Year” in the technology, media and telecommunications (TMT) category, and counsel Jack Sun as “Rising Star of the Year” in the…

Paul, Weiss Recognized at ALB China Law Awards 2021

May 20, 2021
Awards

Paul, Weiss Recognized at ALB China Law Awards 2021

Paul, Weiss won Asian Legal Business’s “M&A Deal of the Year – Premium” award presented at ALB’s annual China Law Awards.

About the Firm

Locations

Resources

Contact Us

Policies & Notices

Subscription Preferences

Browse by Last Name

Search for Professionals

ProfessionalsJack Sun

Jack Sun

Related Resources

Awards & Recognition

Policies & Notices